Inhibitory effect of synthetic histatin 5 on leukotoxin from Actinobacillus actinomycetemcomitans.
Actinobacillus actinomycetemcomitans is a gram-negative bacterium strongly implicated in the pathogenesis of juvenile periodontitis. This periodontal pathogen synthesizes a leukotoxin that destroys human polymorphonuclear leukocytes (PMNs), and this toxin is thought to be responsible for the virulence of A. actinomycetemcomitans. It was therefore of interest to assess whether major virulence factors of periodontal pathogens were neutralized by salivary components. This study focuses on the effect of histatins, components of the nonimmune oral defense system, on leukotoxin activity. Leukotoxin was extracted with polymyxin B from freshly grown anaerobic cultures of A. actinomycetemcomitans strain Y4. PMNs isolated from blood of healthy human volunteers were incubated in a cytotoxicity assay containing PMNs (10(7) cells/ml) and leukotoxin preparation (0-500 microg/ml) in Hanks' balanced salt solution at 37 degrees C for 0-120 min with or without synthetic histatin 5 (0-500 microM). Cytotoxicity was measured by release of lactate dehydrogenase (LDH) at different time intervals. Histatin 5 neutralized the toxic effect of the leukotoxin preparation in a concentration-dependent manner, with an IC(50) value of 150 microM. When PMNs were preincubated with histatin 5 (300 microM), washed and subsequently exposed to leukotoxin, no protective effect was observed. This observation suggests a mechanism of inhibition whereby histatin 5 either directly neutralizes the leukotoxin or interferes with the leukotoxin-PMN interaction. The inhibitory effect of histatin 5 on leukotoxic activity may suggest a new biological function of histatins in the oral cavity as a naturally occurring secondary antibiotic.
Murakami
Y
Y
Department of Periodontology and Oral Biology, Goldman School of Dental Medicine, Boston University, 700 Albany Street, Boston, MA 02118, USA.
Xu
T
T
Helmerhorst
E J
EJ
Ori
G
G
Troxler
R F
RF
Lally
E T
ET
Oppenheim
F G
FG
D000328:Adult; D016976:Aggregatibacter actinomycetemcomitans / Q000378:metabolism* / Q000472:pathogenicity; D000992:Antitoxins / Q000494:pharmacology*; D001427:Bacterial Toxins / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D002470:Cell Survival; D002851:Chromatography, High Pressure Liquid; D003603:Cytotoxins / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005098:Exotoxins / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D054808:Histatins; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000032:analysis; D007928:Lethal Dose 50; D009504:Neutrophils / Q000187:drug effects; D020011:Protective Agents / Q000494:pharmacology; D012471:Salivary Proteins and Peptides / Q000494:pharmacology*; D013997:Time Factors; D014774:Virulence
D000992:Antitoxins; D001427:Bacterial Toxins; D003603:Cytotoxins; D005098:Exotoxins; C068075:HTN3 protein, human; D054808:Histatins; D020011:Protective Agents; D012471:Salivary Proteins and Peptides; C018579:leukotoxin; D007770:L-Lactate Dehydrogenase